370 related articles for article (PubMed ID: 12705679)
21. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
22. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Shultz TR; Tapsall JW; White PA
Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
24. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
25. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
Janoir C; Zeller V; Kitzis MD; Moreau NJ; Gutmann L
Antimicrob Agents Chemother; 1996 Dec; 40(12):2760-4. PubMed ID: 9124836
[TBL] [Abstract][Full Text] [Related]
26. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
Hartman-Neumann S; DenBleyker K; Pelosi LA; Lawrence LE; Barrett JF; Dougherty TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2865-70. PubMed ID: 11557482
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Ruiz J; Marco F; Sierra JM; Aguilar L; Garcia-Mendez E; Mensa J; Jiménez De Anta MT; Vila J
Int J Antimicrob Agents; 2003 Jul; 22(1):73-6. PubMed ID: 12842332
[TBL] [Abstract][Full Text] [Related]
28. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
Stewart BA; Johnson AP; Woodford N
J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
[TBL] [Abstract][Full Text] [Related]
29. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Moine P; Cherbuliez C; Peytavin G; Fantin B; Köhler T
Antimicrob Agents Chemother; 2005 Mar; 49(3):1046-54. PubMed ID: 15728901
[TBL] [Abstract][Full Text] [Related]
30. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
Gould KA; Pan XS; Kerns RJ; Fisher LM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
[TBL] [Abstract][Full Text] [Related]
31. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
32. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
33. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
[TBL] [Abstract][Full Text] [Related]
34. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.
Ruiz J; Jurado A; Garcia-Méndez E; Marco F; Aguilar L; Jiménez de Anta MT; Vila J
J Antimicrob Chemother; 2001 Oct; 48(4):545-8. PubMed ID: 11581235
[TBL] [Abstract][Full Text] [Related]
35. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones].
Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV
Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803
[TBL] [Abstract][Full Text] [Related]
36. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
Jalal S; Wretlind B
Microb Drug Resist; 1998; 4(4):257-61. PubMed ID: 9988043
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
39. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
Patel SN; Melano R; McGeer A; Green K; Low DE
Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
